| Description | Human ITGAL knockout MDA-MB-415 cell line is edited by our special CRISPR/Cas9 technology. MDA-MB-415 cells were derived from the pleural effusion of a 38-year-old woman with breast adenocarcinoma and expressed the WNT7B oncogene. MDA-MB-415 cells are not easily trypsinized. |
| Size | 1 vial (2*106 cells/vial) |
| Parental Cell Line | MDA-MB-415 |
| Biosafety Level | 1 |
| Format | Frozen |
| Culture Conditions | Cells are adherent cells that are cultured at 37℃ with 5% CO2. |
| Culture Medium | DMEM + 10% FBS + 2mM L-Glutamine |
| Subculture Conditions | Split cultures 1:3 using trypsin/EDTA; 37℃, 5% CO2 |
| Derived From | Pleural effusion |
| Freezing Medium | Culture medium + 50% FBS + 10% DMSO |
| Subculture Guidelines | The culture media should be changed every 2-3 days at 1:2 to 1:3. |
| Knockout Validation | Sanger Sequencing, Western Blot (WB) |
| Viability | >95% viability before freezing. |
| Adherent /Suspension | Adherent |
| Disease | Adenocarcinoma |
| Purity | Immunogen affinity purified |
| Storage | Vapor phase of liquid nitrogen |
| Sterility | Mycoplasma negative, HOECHST and PCR |
| Shipping Info | Dry Ice |
| Species | Human |
| Tested Applications | Suitable for: WB |
| Tissue | Breast; mammary gland |
| Recommended Control | Human wild-type MDA-MB-415 cell line |
| Morphology | Epithelial, grown as monolayer |
| Pathogens | HIV: Negative Hepatitis B: Negative Hepatitis C: Negative |
| Tumorigenicity | No, in immunosuppressed mice. Yes, in semisolid medium. |
| Applications | For research use only |
| Product Type | Knockout Stable Cell Line |
| Price | Inquiry |
